890.68
1.75%
-15.86
After Hours:
887.29
-3.39
-0.38%
Regeneron Pharmaceuticals, Inc. stock is currently priced at $890.68, with a 24-hour trading volume of 540.72K.
It has seen a -1.75% decreased in the last 24 hours and a -7.33% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $908.9 pivot point. If it approaches the $890.8 support level, significant changes may occur.
Previous Close:
$906.54
Open:
$911.09
24h Volume:
540.72K
Market Cap:
$97.76B
Revenue:
$13.12B
Net Income/Loss:
$3.95B
P/E Ratio:
25.40
EPS:
35.06
Net Cash Flow:
$3.67B
1W Performance:
-0.37%
1M Performance:
-7.33%
6M Performance:
+11.75%
1Y Performance:
+12.80%
Regeneron Pharmaceuticals, Inc. Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals, Inc.
Sector
Industry
Phone
914-847-7000
Address
777 Old Saw Mill River Road, Tarrytown, NY
Regeneron Pharmaceuticals, Inc. Stock (REGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
Aug-21-23 | Reiterated | Oppenheimer | Perform |
Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
Jun-06-22 | Initiated | Jefferies | Underperform |
May-23-22 | Initiated | SVB Leerink | Outperform |
Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
Dec-09-21 | Resumed | Wells Fargo | Overweight |
Dec-07-21 | Resumed | Cowen | Market Perform |
Dec-06-21 | Initiated | Goldman | Buy |
Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
Jun-29-21 | Initiated | H.C. Wainwright | Buy |
Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
Apr-08-20 | Initiated | The Benchmark Company | Hold |
Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
Feb-27-20 | Initiated | Barclays | Overweight |
Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
Feb-11-20 | Upgrade | Argus | Hold → Buy |
Dec-24-19 | Initiated | Raymond James | Mkt Perform |
Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Nov-12-19 | Initiated | SunTrust | Hold |
Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
Oct-17-19 | Resumed | BofA/Merrill | Neutral |
Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals, Inc. Stock (REGN) Latest News
EXEL vs. REGN: Which Stock Is the Better Value Option?
Zacks Investment Research
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks Investment Research
Regeneron (REGN) Reports Next Week: What You Should Expect
Zacks Investment Research
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Zacks Investment Research
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Zacks Investment Research
Regeneron Pharmaceuticals, Inc. Stock (REGN) Financials Data
Regeneron Pharmaceuticals, Inc. (REGN) Revenue 2024
REGN reported a revenue (TTM) of $13.12 billion for the quarter ending December 31, 2023, a +7.76% rise year-over-year.
Regeneron Pharmaceuticals, Inc. (REGN) Net Income 2024
REGN net income (TTM) was $3.95 billion for the quarter ending December 31, 2023, a -8.87% decrease year-over-year.
Regeneron Pharmaceuticals, Inc. (REGN) Cash Flow 2024
REGN recorded a free cash flow (TTM) of $3.67 billion for the quarter ending December 31, 2023, a +7.93% increase year-over-year.
Regeneron Pharmaceuticals, Inc. (REGN) Earnings per Share 2024
REGN earnings per share (TTM) was $34.75 for the quarter ending December 31, 2023, a -9.13% decline year-over-year.
Regeneron Pharmaceuticals, Inc. Stock (REGN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
RYAN ARTHUR F | Director |
Apr 01 '24 |
Sale |
962.53 |
100 |
96,253 |
18,182 |
MURPHY ANDREW J | EVP Research |
Mar 14 '24 |
Sale |
956.47 |
5,783 |
5,531,290 |
48,306 |
MURPHY ANDREW J | EVP Research |
Mar 13 '24 |
Option Exercise |
399.66 |
20,000 |
7,993,200 |
68,306 |
McCourt Marion | EVP Commercial |
Mar 01 '24 |
Sale |
967.50 |
358 |
346,365 |
13,431 |
RYAN ARTHUR F | Director |
Mar 01 '24 |
Sale |
982.05 |
100 |
98,205 |
18,282 |
SING GEORGE L | Director |
Feb 26 '24 |
Option Exercise |
413.33 |
1,000 |
413,330 |
26,849 |
Bassler Bonnie L | Director |
Feb 26 '24 |
Option Exercise |
391.92 |
854 |
334,700 |
2,236 |
SING GEORGE L | Director |
Feb 26 '24 |
Sale |
992.50 |
1,000 |
992,500 |
26,349 |
LAROSA JOSEPH J | EVP General Counsel and Secret |
Feb 26 '24 |
Sale |
990.00 |
1,000 |
990,000 |
36,543 |
Bassler Bonnie L | Director |
Feb 26 '24 |
Sale |
979.25 |
854 |
836,280 |
1,382 |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Cap:
|
Volume (24h):